GLP-1 Medications Show Promise in Breast Cancer Care, Large Study Reveals
Table of Contents
A new analysis suggests a potential link between glucagon-like peptide 1 (GLP-1) receptor agonists – medications primarily used for weight management – and reduced tumor activity in breast cancer patients. The findings, presented at the 2025 San Antonio Breast Cancer Symposium, highlight disparities in access to these therapies and call for further research into their potential role in oncology.
The study, one of the largest real-world investigations of its kind, analyzed electronic health records from 708,406 patients diagnosed with breast cancer between January 2011 and February 2025. Researchers utilized AI-assisted data extraction to evaluate documented GLP-1 use, associated clinical factors, and correlations with circulating tumor DNA (ctDNA) testing and positivity.
Who is Receiving GLP-1 Therapy?
Overall, 7.6% of patients in the study had documented GLP-1 use, primarily for conditions such as diabetes, weight loss, cardiovascular issues, or obstructive sleep apnea. The research revealed significant variations in usage patterns across different patient groups.
GLP-1 therapy was more prevalent among individuals with a body mass index (BMI) of 30 or higher, non-Latinx Black patients, those who utilized telemedicine, and residents of rural areas. Conversely, use was lower among patients over the age of 75, those with stage IV disease, individuals with HR-/HER2- tumors, Latinx and Asian patients, people with limited English proficiency, and those receiving care at community medical centers rather than academic institutions. This disparity underscores the influence of social determinants of health (SDOH) on access to care.
Potential Impact on Tumor Activity
The study revealed a notable association between GLP-1 use and both increased ctDNA testing rates (2.8% vs. 1.5%) and decreased ctDNA positivity (25.8% vs. 31.6%). “These findings suggest a potential connection between GLP-1 therapy and reduced circulating tumor activity,” one researcher stated. This raises the possibility that these medications could offer a supportive benefit in oncology care, extending beyond their established role in weight management.
Addressing Disparities and Charting Future Research
The analysis emphasizes the critical role of clinical factors, sociodemographic characteristics, and SDOH in shaping GLP-1 utilization. Researchers stressed the need for additional studies to definitively determine whether GLP-1 medications directly impact breast cancer outcomes and to ensure equitable access to these potentially beneficial therapies across diverse patient populations.
This investigation provides valuable new insights into the potential benefits of GLP-1s in breast cancer care and opens avenues for future research. The study’s findings underscore the importance of considering the broader context of patient health and access when evaluating treatment options.
Reference
Ryals CA et al. Real-world glucagon-like peptide 1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer. Abstract PD8-07-02. SABCS 2025; 9-12 December.
